This is a single blind, dose escalating, placebo-controlled, crossover study of
gluten-degrading drug PvP001 administered to healthy volunteers (age 18-64 years). Subjects
will be randomized to one of three groups representing different levels of gluten exposure -
low, medium, or high - in a single meal. Within each gluten exposure group, increasing doses
of PvP001 (or placebo) will be administered.